{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-019405","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2022-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.669461+00:00","generated_at":"2026-06-23T04:20:49.079142+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biodesix preliminary Q3 revenue $10.6M-$11.2M, core lung diagnostics up 96-103% YoY","bullets":["Total Q3 2022 revenue estimated $10.6M-$11.2M, up 62-71% YoY.","Core lung diagnostic testing revenue $8.9M-$9.2M, a 96-103% increase YoY.","COVID testing revenue $1.1M-$1.3M, up 117-157% YoY; expects immaterial in Q4.","Biopharma services revenue $0.6M-$0.7M, down 53-60% YoY due to clinical study delays.","Cash and equivalents $15.2M as of Sep 30; expects FY2022 revenue near high end of $37.5M-$39.5M guidance range."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-019405","json":"https://secwatch.observer/filing/0000950170-22-019405.json","markdown":"https://secwatch.observer/filing/0000950170-22-019405.md","text":"https://secwatch.observer/filing/0000950170-22-019405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022019405/0000950170-22-019405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022019405/bdsx-20221011.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:20:49.079142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}